Two Sigma Advisers LP Raises Stake in Cencora, Inc. (NYSE:COR)

Two Sigma Advisers LP lifted its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 0.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,639,300 shares of the company's stock after purchasing an additional 900 shares during the quarter. Cencora comprises about 0.9% of Two Sigma Advisers LP's portfolio, making the stock its 29th biggest position. Two Sigma Advisers LP owned approximately 0.85% of Cencora worth $368,318,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Whittier Trust Co. grew its stake in shares of Cencora by 0.6% during the fourth quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock worth $1,765,000 after acquiring an additional 44 shares during the last quarter. Shepherd Financial Partners LLC raised its position in shares of Cencora by 0.9% in the 4th quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company's stock valued at $1,223,000 after purchasing an additional 46 shares during the last quarter. WASHINGTON TRUST Co raised its position in shares of Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after purchasing an additional 46 shares during the last quarter. JFS Wealth Advisors LLC increased its stake in Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after purchasing an additional 46 shares in the last quarter. Finally, Cullen Frost Bankers Inc. raised its holdings in shares of Cencora by 1.1% in the fourth quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company's stock worth $1,003,000 after buying an additional 47 shares during the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Cencora

In other news, EVP Silvana Battaglia sold 5,000 shares of the company's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares of the company's stock, valued at $3,724,197.76. This represents a 24.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 14,579 shares of the company's stock in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the sale, the chairman now directly owns 315,913 shares of the company's stock, valued at approximately $89,027,442.53. This represents a 4.41% decrease in their position. The disclosure for this sale can be found here. Insiders sold 50,223 shares of company stock valued at $13,580,967 over the last quarter. 10.80% of the stock is currently owned by insiders.

Cencora Price Performance

COR stock traded down $1.33 during mid-day trading on Thursday, reaching $290.03. 1,057,854 shares of the company's stock were exchanged, compared to its average volume of 1,545,015. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $309.35. The stock's 50 day moving average is $281.86 and its 200 day moving average is $256.65. The company has a market cap of $56.21 billion, a price-to-earnings ratio of 41.26, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.07 by $0.35. The business had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The company's revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $3.80 earnings per share. On average, research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 2nd. Shareholders of record on Friday, May 16th will be paid a dividend of $0.55 per share. The ex-dividend date is Friday, May 16th. This represents a $2.20 annualized dividend and a yield of 0.76%. Cencora's dividend payout ratio (DPR) is currently 25.52%.

Analysts Set New Price Targets

Several research firms recently issued reports on COR. JPMorgan Chase & Co. upped their target price on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Wall Street Zen raised Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Morgan Stanley set a $288.00 target price on Cencora in a report on Tuesday, April 15th. Robert W. Baird upped their target price on Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Finally, UBS Group raised their price target on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $301.18.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.